The ONCOS-102 phase 1b melanoma study is published in the prestigious scientific journal Clinical Cancer Research
· ONCOS-102 in combination with PD-1 checkpoint inhibitor (CPI) Keytruda demonstrated strong ORR of 35% in PD-1 CPI resistant melanoma, correlating with robust and persistent immune activation · A phase 2 trial is under planning, where ONCOS-102 will be tested in a triple-combination with both PD-1 and CTLA-4 CPIs Oslo, Norway, 20 October 2022 – Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target solid tumors, today announces that the completed ONCOS-102 phase 1b study in PD-1 CPI resistant advanced melanoma has been published in